Institutional Setting Becomes Marketing Bedrock For Avanir’s “Laughing” Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Since obtaining FDA approval of Neudexta in pseudobulbar affect in October 2010, Avanir has seen sales grow incrementally, but continues to learn about opportunities in the emotional incontinence market.